<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="long as the COVID-19 resource centre remains active. As the" exact="coronavirus disease" post="2019 (COVID-19) spreads, efforts are being made to reduce"/>
 <result pre="as the COVID-19 resource centre remains active. As the coronavirus" exact="disease" post="2019 (COVID-19) spreads, efforts are being made to reduce"/>
 <result pre="higher than 1·5 or the proportion of contacts traced is" exact="lower" post="than 80%. One of the main assumptions of the"/>
 <result pre="model by Hellewell and colleagues is that all individuals with" exact="symptomatic" post="infection with severe acute respiratory syndrome (SARS) coronavirus 2"/>
 <result pre="by Hellewell and colleagues is that all individuals with symptomatic" exact="infection" post="with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2)"/>
 <result pre="colleagues is that all individuals with symptomatic infection with severe" exact="acute" post="respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) are eventually tested"/>
 <result pre="is that all individuals with symptomatic infection with severe acute" exact="respiratory" post="syndrome (SARS) coronavirus 2 (SARS-CoV-2) are eventually tested and"/>
 <result pre="that all individuals with symptomatic infection with severe acute respiratory" exact="syndrome" post="(SARS) coronavirus 2 (SARS-CoV-2) are eventually tested and reported."/>
 <result pre="for such an approach is the high estimates for the" exact="secondary" post="attack rates of SARS-CoV-2 in households (∼15%) and among"/>
 <result pre="variety of microbial pathogens, and in reducing the risk of" exact="secondary" post="spread of infection. Based on experiences with PEP for"/>
 <result pre="been recommended by WHO for people at high risk of" exact="infection" post="before or after exposure to pandemic influenza.3 Antiviral drugs"/>
 <result pre="after symptom onset can reduce infectiousness to others by reducing" exact="viral" post="shedding in the respiratory secretions of patients (SARS-CoV-2 viral"/>
 <result pre="reduce infectiousness to others by reducing viral shedding in the" exact="respiratory" post="secretions of patients (SARS-CoV-2 viral load in sputum peaks"/>
 <result pre="reducing viral shedding in the respiratory secretions of patients (SARS-CoV-2" exact="viral" post="load in sputum peaks at around 5–6 days after"/>
 <result pre="drug, hydroxychloroquine, is licensed for the chemoprophylaxis and treatment of" exact="malaria" post="and as a disease-modifying antirheumatic drug. It has a"/>
 <result pre="that prophylaxis with hydroxychloroquine at approved doses could prevent SARS-CoV-2" exact="infection" post="and ameliorate viral shedding.5 Clinical trials of hydroxychloroquine treatment"/>
 <result pre="hydroxychloroquine at approved doses could prevent SARS-CoV-2 infection and ameliorate" exact="viral" post="shedding.5 Clinical trials of hydroxychloroquine treatment for COVID-19 pneumonia"/>
 <result pre="ameliorate viral shedding.5 Clinical trials of hydroxychloroquine treatment for COVID-19" exact="pneumonia" post="are underway in China (NCT04261517 and NCT04307693). We are"/>
 <result pre="be infected, and the efficacy of prophylactic hydroxychloroquine in preventing" exact="secondary" post="SARS-CoV-2 infections and disease symptoms among all contacts. Our"/>
 <result pre="and the efficacy of prophylactic hydroxychloroquine in preventing secondary SARS-CoV-2" exact="infections" post="and disease symptoms among all contacts. Our objective is"/>
 <result pre="efficacy of prophylactic hydroxychloroquine in preventing secondary SARS-CoV-2 infections and" exact="disease" post="symptoms among all contacts. Our objective is to evaluate"/>
 <result pre="to evaluate the reduction in transmissibility of SARS-CoV-2 and in" exact="disease" post="progression among the contacts of an index case. The"/>
 <result pre="for Ebola in 2015.6 A person newly diagnosed with the" exact="disease" post="becomes the index case, around whom an epidemiologically defined"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March 9.10.1093/cid/ciaa237"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020published online March 9.10.1093/cid/ciaa237 5TettSECutlerDJDayROBrownKFBioavailability"/>
</results>
